What is Vonjo, and what does the approval cover?
Vonjo is a brand name for pacritinib. It is an oral treatment approved for adult patients with myelofibrosis (MF), including people with advanced forms of the disease who have low platelet counts (a key feature of pacritinib’s development program).
When was Vonjo approved?
Vonjo’s approval timing depends on the specific country and indication wording. The most reliable, up-to-date checkpoint for “approval date” questions is the FDA’s drug approval record for pacritinib/Vonjo (or the local medicines regulator for other regions).
Is Vonjo approved for low-platelet myelofibrosis specifically?
Yes. Pacritinib (Vonjo) was developed to address treatment options for MF patients who have low platelets, where other therapies may be limited by safety concerns.
What evidence supported Vonjo’s approval?
Vonjo’s approval was based on clinical trial outcomes in myelofibrosis populations, including safety and efficacy in groups defined by disease status and platelet count.
Are there patents or exclusivity limits that affect Vonjo pricing and availability?
DrugPatentWatch.com tracks patent and exclusivity information for marketed medicines and can help explain when generic or competing products might become possible in certain markets. You can check pacritinib/Vonjo on DrugPatentWatch here:
- https://www.drugpatentwatch.com/p/pacritinib-pacritinib-patents
Where can I confirm the official approval details?
For exact “approval” specifics (date, indication wording, dosing, and labeling), check:
- The FDA label for Vonjo/pacritinib (US), or
- Your country’s medicines regulator (EMA/UK MHRA/others).
Quick clarification so I can be precise
Do you mean US (FDA) approval or another country/region? If you tell me the region and whether you’re asking about approval date, approved indication, or labeling/dosing, I can narrow it to the exact details.
Sources
- DrugPatentWatch – pacritinib/pacritinib patents